In 2018, we started a prospective pilot study of preoperative concurrent chemoradiotherapy (PCRT) in HER2+ or triple negative (TN) breast cancer patients to test feasibility and tolerance of this combination and secondarily to evaluate pathological response and oncological outcomes. The gene discussed is ERBB2; the disease is breast carcinoma.